Skip to main content
Log in

The Aldosterone Renin Ratio (ARR) APP as Tool to Enhance the Detection Rate of Primary Aldosteronism

  • Short Communication
  • Published:
High Blood Pressure & Cardiovascular Prevention Aims and scope Submit manuscript

Abstract

Primary aldosteronism is one of the most common forms of secondary hypertension, but it is often under diagnosed, which leads to the development of cardiovascular damage, and excess costs for long-term drug treatment and management of complications. The aldosterone to renin ratio (ARR) is a key step for early detection of primary aldosteronism, but unfortunately is not easily estimated. This is because plasma aldosterone and renin are measured with different assays, which provide results in different units of measure, with ensuing difficulty of obtaining the calculation of the ARR in the proper units and impossibility of interpreting results with reference to established cut off values. Therefore, doctors are often unable to draw unambiguous conclusions to be used for the clinical decision-making. To the aim of making the diagnostic work-up easier, we have developed an Application that provide a swift calculation of the ARR regardless of the units of measure used for plasma aldosterone and renin values. If the concomitant serum potassium level is available the App also provides the patient’s probability of having an aldosterone—producing adenoma based on a validated logistic discriminant analysis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Rossi GP, Bernini G, Caliumi C, et al. PAPY Study Investigators. A prospective study of the prevalence of primary aldosteronism in 1125 hypertensive patients. J Am Coll Cardiol. 2006;48:2293–300.

    Article  CAS  PubMed  Google Scholar 

  2. Rossi GP, Sechi LA, Giacchetti G, et al. Primary aldosteronism: cardiovascular, renal and metabolic implications. Trends Endocrinol Metab. 2008;19:88–90.

    Article  CAS  PubMed  Google Scholar 

  3. Lubitz CC, Economopoulos KP, Sy S, et al. Cost-effectiveness of screening for primary aldosteronism and subtype diagnosis in the resistant hypertensive patients. Circ Cardiovasc Qual Outcomes. 2015;8:621–30.

    Article  PubMed  Google Scholar 

  4. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:3266–81.

    Article  Google Scholar 

  5. Nishikawa T, Omura M, Satoh F, et al. Guidelines for the diagnosis and treatment of primary aldosteronism—the Japan Endocrine Society 2009. Endocr J. 2011;58:711–21.

    Article  CAS  PubMed  Google Scholar 

  6. Rossi GP, Auchus RJ, Brown M, et al. An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism. Hypertension. 2014;63:151–60.

    Article  CAS  PubMed  Google Scholar 

  7. Rossi GP. A comprehensive review of the clinical aspects of primary aldosteronism. Nat Rev Endocrinol. 2011;7:485–95.

    Article  PubMed  Google Scholar 

  8. Mulatero P, Stowasser M, Loh KC, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab. 2004;89:1045–50.

    Article  CAS  PubMed  Google Scholar 

  9. Hiramatsu K, Yamada T, Yukimura Y, et al. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch Intern Med. 1981;141:1589–93.

    Article  CAS  PubMed  Google Scholar 

  10. Rossi GP, Seccia TM, Palumbo G, et al. Primary Aldosteronism in the Prevalence in hYpertension (PAPY) Study Investigators. Within-patient reproducibility of the aldosterone: renin ratio in primary aldosteronism. Hypertension. 2010;55:83–9.

    Article  CAS  PubMed  Google Scholar 

  11. Rossi GP, Rossi E, Pavan E, et al. Screening for primary aldosteronism with a logistic multivariate discriminant analysis. Clin Endocrinol (Oxf). 1998;49:713–23.

    Article  CAS  PubMed  Google Scholar 

  12. Rossi GP, Ceolotto G, Rossitto G, Seccia TM, Maiolino G, Berton C, Basso D, Plebani M. Prospective validation of an automated chemiluminescence-based assay of renin and aldosterone for the work-up of arterial hypertension. Clin Chem Lab Med. 2016. doi:10.1515/cclm-2015-1094.

    PubMed  Google Scholar 

Download references

Acknowledgments

There are conflicts of interest to declare. We are grateful to Teresa Maria Seccia, MD, PhD, Giuseppe Maiolino, MD, PhD, and Giacomo Rossitto, MD, for helpful discussion.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Gian Paolo Rossi.

Ethics declarations

Conflict of interest and sources of funding

All other authors declare that they have no conflict of interest. Grant support: FORICA (The FOundation for advanced Research In Hypertension and CArdiovascular diseases, http://www.forica.it), the Società Italiana dell’Ipertensione Arteriosa and the University of Padua to GPR. Research grant by the Young Research Program of the Italy’s Health Minister to L.L. Project GR-2009-1524351. No relationship with industry to be disclosed.

Disclosure summary

All authors have nothing to disclose

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (MP4 6045 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rossi, G.P., Bisogni, V. The Aldosterone Renin Ratio (ARR) APP as Tool to Enhance the Detection Rate of Primary Aldosteronism. High Blood Press Cardiovasc Prev 23, 147–149 (2016). https://doi.org/10.1007/s40292-016-0132-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40292-016-0132-9

Keywords

Navigation